Sirnaomics Ltd. (2257) AI Stock Analysis

• Market Cap: HK$475.35M
• Dividend Yield: N/A
• Average Volume (3M): 364.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: N/A
• EPS Growth: 31.23%
• Country: HK
• Employees: 69
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -5.18
• Shares Outstanding: 105,166,176
• 10 Day Avg. Volume: 516,415
• 30 Day Avg. Volume: 364,848
• PEG Ratio: -0.03
• Price to Book (P/B): -18.42
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: 0.08
• Enterprise Value/Revenue: 7.92
• Enterprise Value/Gross Profit: 31.29
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: HK$4.50 ▼(-0.44%Downside)

The stock score reflects significant financial challenges due to consistent losses and a weak balance sheet, which are major concerns. However, the strong technical indicators and positive market momentum provide some optimism. The negative valuation metrics further underscore the financial risks, making the stock less attractive, especially for value-focused investors.

Sirnaomics Ltd. Business Overview & Revenue Model

Company Description

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.

How the Company Makes Money

Sirnaomics Ltd. generates revenue primarily through the development and commercialization of its RNAi therapeutics. The company's revenue model includes income from licensing agreements, where it partners with other pharmaceutical companies to co-develop and commercialize its drug candidates. Additionally, Sirnaomics may receive milestone payments and royalties from these partnerships as products advance through clinical trials and reach the market. Government grants and funding from research institutions may also contribute to its revenue, supporting its ongoing research and development efforts.

Sirnaomics Ltd. Financial Statement Overview

Summary

Sirnaomics Ltd. faces significant financial challenges with persistent operating losses and a weak balance sheet characterized by negative equity. Despite some revenue growth and improvements in free cash flow, the company remains unprofitable with high cash burn, raising concerns about its ability to sustain operations without further financing.

Income Statement

The company's income statement reveals ongoing challenges in profitability and revenue growth. Despite an increase in revenue from the previous year, the net profit margin remains deeply negative at -289.0% for 2024, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Although the gross profit margin is positive at 67.4%, it is insufficient to offset the high operating expenses.

Balance Sheet

The balance sheet indicates a precarious financial position with negative stockholders' equity, signaling insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, but the company has managed to maintain a relatively low total debt level. The equity ratio is negative, reflecting a higher liability level than assets, which poses a financial stability risk.

Cash Flow

The cash flow statement shows a significant negative free cash flow, indicating cash burn exceeding income. The operating cash flow to net income ratio is negative, highlighting cash outflows in operations. However, there is a noticeable improvement in free cash flow, which grew positively from 2023 to 2024, suggesting some progress towards better cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.78M	397.00K	705.00K	71.00K	0.00
Gross Profit	1.20M	397.00K	705.00K	71.00K	0.00
EBITDA	-31.12M	-72.36M	-89.02M	-55.87M	-19.27M
Net Income	-51.38M	-78.69M	-88.30M	-213.07M	-43.77M
Balance Sheet
Total Assets	28.33M	75.79M	163.93M	240.65M	110.18M
Cash, Cash Equivalents and Short-Term Investments	11.77M	43.93M	105.23M	211.99M	103.12M
Total Debt	8.06M	8.85M	10.76M	7.04M	2.88M
Total Liabilities	44.33M	51.33M	52.37M	30.36M	204.36M
Stockholders Equity	-1.68M	40.20M	122.01M	211.62M	-94.43M
Cash Flow
Free Cash Flow	-19.84M	-72.03M	-107.54M	-62.85M	-21.15M
Operating Cash Flow	-19.73M	-70.29M	-88.71M	-56.97M	-19.00M
Investing Cash Flow	2.14M	-5.35M	-32.61M	-6.04M	8.39M
Financing Cash Flow	5.82M	-5.61M	15.89M	170.96M	100.37M

Sirnaomics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Positive. The current price of 4.52 is above the 20-day moving average (MA) of 3.91, above the 50-day MA of 3.39, and above the 200-day MA of 3.19, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 60.21 is Neutral, neither overbought nor oversold. The STOCH value of 43.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2257.

Sirnaomics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	68 Neutral	HK$1.48B	36.94	4.92%	―	38.48%	―
2257	56 Neutral	HK$475.35M	―	-266.90%	―	―	31.23%
3681	56 Neutral	HK$2.51B	―	-75.64%	―	42.21%	29.52%
2616	55 Neutral	HK$5.50B	―	-22.23%	―	-14.17%	76.00%
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
6628	47 Neutral	HK$610.93M	―	-32.59%	―	-79.65%	37.50%
2197	45 Neutral	HK$330.75M	―		―	-1.73%	-689.53%

Sirnaomics Ltd. Corporate Events

Sirnaomics Ltd. AGM Resolutions Passed, Paving Way for Strategic Growth

Sirnaomics Ltd. announced the successful passing of all resolutions at its Annual General Meeting held on June 20, 2025. Key decisions included the re-election of directors, re-appointment of auditors, and granting mandates for share issuance and buybacks, reflecting strong shareholder support and strategic positioning for future growth.

Sirnaomics Ltd. Announces Board Composition and Committee Roles

Sirnaomics Ltd. has announced the composition of its board of directors, highlighting key roles and committee memberships. The board includes Dr. Poon Hung Fai as the CEO and executive director, with Ms. Monin Ung serving as the chairlady. The announcement also details the structure of the company’s audit, nomination, and remuneration committees, which are crucial for corporate governance and strategic decision-making.

Sirnaomics Ltd. Updates Nomination Committee Terms

Sirnaomics Ltd. has amended the terms of reference for its Nomination Committee, initially adopted in December 2021. The committee, which plays a crucial role in the governance of the company, is composed of at least three directors, with a majority being independent non-executive directors and at least one member of a different gender. This amendment underscores the company’s commitment to diversity and effective governance, potentially enhancing its industry positioning and stakeholder confidence.

Sirnaomics Ltd. Announces Annual General Meeting Details

Sirnaomics Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, and authorization for the board to manage director remuneration and share allotment. These resolutions are crucial for the company’s governance and strategic direction, potentially impacting its market operations and stakeholder interests.

Sirnaomics Ltd. Announces Management Restructuring

Sirnaomics Ltd. announced the cessation of Dr. Yang Lu as the Honorary Scientific Advisor and from all positions within the company and its subsidiaries, effective April 23, 2025. This change is intended to allow the new management team to concentrate on enhancing internal control measures and ensuring regulatory compliance, with the company stating that this will not adversely affect its business operations.

Sirnaomics Reports 2024 Annual Results and Strategic Progress

Sirnaomics Ltd. announced its audited consolidated annual results for 2024, highlighting significant progress in its RNAi therapeutics pipeline despite a challenging global economic environment. The company achieved key milestones, including advancements in clinical trials for its STP705 and STP707 programs, and the GalAhead™ platform. Sirnaomics implemented strategic restructuring and cost rationalization to enhance operational efficiency, focusing on high-potential programs and extending its cash runway, positioning itself for sustainable growth.